PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes

The manuscript, "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," published in the journal Diagnostics, reported that EsoCheck cell collection was rapid, well tolerated, and consistent across operators, including newly trained personnel.

"These findings provide compelling real-world evidence supporting the feasibility of large-scale implementation of EsoGuard testing," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "With EsoGuard now fully reimbursed by Medicare nationwide, efficient and scalable clinical implementation will be critical as we accelerate commercialization across diverse clinical settings in the coming months."

The study included 11,991 patients with clinical risk factors who underwent EsoGuard testing on samples collected with EsoCheck between January 2023 and June 2024. Cell collection was successful in 95% of patients, with an average collection time of less than two  minutes and no reported device-related adverse events. In a post-procedure survey, 82% reported very low discomfort and only 0.2% rated it as high. 96%  would recommend the test to others, and 95% said they would undergo it again if clinically indicated.

"We are very encouraged by the real-world performance of adveEsoGuard and EsoCheck in this large cohort of patients referred for esophageal precancer testing," said Victoria T. Lee, M.D., Lucid's Chief Medical Officer. "The high cell collection success rate across operators, including among newly trained personnel, high patient satisfaction scores, and short average procedure time strongly support large-scale implementation to broadly expand access to esophageal precancer testing in at-risk patients."